伊尔贝沙坦通过抗氧化剂和抗瘤途径对脂聚糖类诱导的心脏毒性有治愈作用
Muhammet Yusuf Tepebaşi1, Halil Aşci2, Samet Coşan2
1Department of Medical Genetics, University of Süleyman Demirel, Isparta, TR, Turkey.
概括
伊尔贝沙坦 (IRB) 治疗改善了暴露于脂聚糖 (LPS) 诱导的败血症的老鼠的心脏功能. IRB减轻了心肌损伤,氧化应激和亡,这表明它对LPS心脏有毒性的保护作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学 是一个学科.
- 毒理学 毒理学 毒理学
背景情况:
- 脂聚糖 (LPS) 诱导心肌炎症,氧化应激,亡和心脏功能障碍,导致败血症和潜在的死亡.
- 血管激素受体对抗剂,如伊尔贝沙坦 (IRB),正在研究它们对抗LPS诱导的心脏毒性的潜力.
研究的目的:
- 调查伊尔贝沙坦 (IRB) 对脂聚糖 (LPS) 诱导的心脏毒性的保护作用.
- 在LPS诱导的败血症模型中评估IRB对氧化应激,亡和心脏功能障碍标记物的影响.
主要方法:
- 威斯塔尔白性大鼠被分为对照组,LPS-only组和LPS+IRB组.
- 在血清和心脏组织中评估了氧化应激标志物 (总氧化状态,总抗氧化状态,氧化应激指数,缺血变异性白蛋白).
- 测量了心脏酶水平 (CK,CK-MB,LDH) 和分析了与亡相关的基因 (Bcl-2,BAX,p53,caspase-3) 和Sirtuin的mRNA表达.
- 对心脏和大动脉组织进行免疫组织化学和组织病理学检查.
主要成果:
- 使用LPS显著增加了心脏损伤,氧化应激和亡的标志物.
- 在暴露于LPS的老鼠中,IRB治疗显示了所有测量参数的改善,表明心脏损伤减少.
- IRB有效地抵消了LPS对心脏氧化应激和亡通路的有害影响.
结论:
- 伊尔贝沙坦 (IRB) 显示出显著的改善作用,对肌肉心脏损伤诱导的LPS相关的败血症.
- 通过减少心脏中的氧化应激和亡,IRB减轻了LPS诱导的心脏毒性.
- 这些发现表明IRB是治疗LPS引起的心脏并发症的潜在治疗剂.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
786
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
786
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:25Antihypertensive Drugs: Direct Renin Inhibitors
699
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
699
01:22Heart Failure Drugs: Diuretics
424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424
01:26Heart Failure Drugs: Inotropic Agents
635
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
635